The x-axis shows the number of positive tests, and the y-axis shows the probabilities. Treos Bio ZRT OBERTO -101 Amendment 3 Product: PolyPEPI 1018 Colorectal Cancer Vaccine Page 67 of 81 CONFIDENTIAL Figure 4. Distribution of the Expected Number of Positive Tests Based on the simulation, at least 7 subjects are expected to have an immune response against 2 or more cancer antigens with at least 97.5% probability. The expected distribution of probabilities having a given number of subjects with positive immune response for 2 or more antigens is displayed in Figure 5, the x-axis shows the number of subjects with a given probability and the y- axis shows the probability. 00.010.020.030.040.050.060.070.08 0 10 20 30 40 50 60 70 80 Treos Bio ZRT OBERTO -101 Amendment 3 Product: PolyPEPI 1018 Colorectal Cancer Vaccine Page 68 of 81 CONFIDENTIAL Figure 5. Expected Distribution of Probabilities Having a Given Number of Subjects with Positive Immune Response for Two or More Antigens 00.050.10.150.20.250.30.350.40.45 0 1 2 3 4 5 6 7 8 9 10 Treos Bio ZRT OBERTO -101 Amendment 3 Product: PolyPEPI 1018 Colorectal Cancer Vaccine Page 69 of 81 CONFIDENTIAL 10 ETHICAL AND LEGAL CONSIDERATIONS 10.1 Compliance Statement This study will be conducted in accordance with the protocol and with ICH GCP guidelines, as well as all applicable country and regional legal and regulatory requirements. The investigator is responsible for ensuring that this protocol, the site’s ICF, and any other information that will be presented to potential subjects are reviewed and approved by the appropriate IRB or IEC prior to the enrollment of any study subject s.